Informations:
Erreur:
ID
22171
Description
This is an open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's Disease. GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00381238?term=NCT00381238&rank=1
Lien
https://clinicaltrials.gov/ct2/show/NCT00381238?term=NCT00381238&rank=1
Mots-clés
Versions (2)
- 09/05/2017 09/05/2017 -
- 22/05/2017 22/05/2017 -
Téléchargé le
22 mai 2017
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Investigational Product Discontinuation Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease NCT00381238
Investigational Product Discontinuation Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease NCT00381238
Similar models
Investigational Product Discontinuation Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease NCT00381238
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Investigational Product Discontinuation - Rosiglitazone
C0013230 (UMLS CUI-1)
C0457454 (UMLS CUI-2)
C0457454 (UMLS CUI-2)
Investigational Product
Item
Was the investigational product stopped permanently before the end of the scheduled treatment period?
boolean
C0304229 (UMLS CUI [1])
Item
If Yes, check the primary reason the investigational product was stopped:
integer
C0304229 (UMLS CUI [1,1])
C0457454 (UMLS CUI [1,2])
C0457454 (UMLS CUI [1,2])
CL Item
Adverse Event (1)
CL Item
Lost to follow-up (2)
CL Item
Protocol violation (3)
CL Item
Subject decided to withdraw from the study (4)
CL Item
Lack of efficacy (5)
CL Item
Sponsor terminated study (6)
CL Item
Disease progression (7)
CL Item
Other, specify (8)
Specification other
Item
Specify other:
text
C0304229 (UMLS CUI [1,1])
C2348235 (UMLS CUI [1,2])
C2348235 (UMLS CUI [1,2])